Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19
NCT04607928
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
148
Enrollment
OTHER
Sponsor class
Conditions
Fibrotic Pulmonary Sequelae Post-COVID19 Infection
Interventions
DRUG:
Pirfenidone
DRUG:
Placebo
Sponsor
Institut d'Investigació Biomèdica de Bellvitge